Skip to main content
. 2015 Nov 17;5:16344. doi: 10.1038/srep16344

Figure 6. Anti-TNF mAb therapy promotes DMT1 expression in intestinal mucosa and improves anemia in CD patients.

Figure 6

Active CD patients (n = 72) received treatment with anti-TNF mAb (IFX) as indicated, and the disease activity and efficacy of IFX therapy were assessed 12 weeks after the first infusion. (A) Intestinal biopsies were taken from these CD patients 12 weeks after the first IFX infusion, and the mRNA levels of DMT1 were detected by qRT-PCR. Gene expression was normalized to GAPDH mRNA levels in each sample. (B) Sera were collected from these CD patients before and weeks 12 after the first IFX infusion. Hb was then analyzed and the percent of the LRL of Hb was compared. Data are expressed as mean ± SEM. Mann-Whitney test was used for statistical analysis. *P < 0.05, **P < 0.01 versus the data before therapy. The data are a representative of 3 independent experiments. Remission (clinical remission group, n = 38), response (clinical response group, n = 20), failure (clinical failure group, n = 14).